Overview

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

Status:
Terminated
Trial end date:
2018-01-31
Target enrollment:
Participant gender:
Summary
This was a study of INCB054329 given to patients with advanced malignancies that were conducted in three treatment groups. Each treatment group had a dose escalation (Part 1) and a dose expansion (Part 3), two of the treatment groups also had an intra-patient dose titration (Part 2).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Incyte Corporation
Treatments:
INCB054329